According to @StockMKTNewz, Novo Nordisk (NVO) lowered its direct-to-consumer weight-loss drug price for existing cash-paying patients to $349 per month from $499, a $150 (approximately 30 percent) cut, source: @StockMKTNewz citing CNBC. This change translates to roughly $1,800 less in annual out-of-pocket costs per patient at the stated price points, source: @StockMKTNewz citing CNBC. No direct crypto market impact or specific product names were disclosed by the source, which focused solely on the pricing adjustment, source: @StockMKTNewz citing CNBC.